New Insights Into the Persistent Pain of UTIs
MONDAY, March 4, 2024 -- People with recurring urinary tract infections frequently have persistent pain, even after antibiotics have cleared the harmful bacteria from their system. Now, researchers have figured out why this perplexing problem... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 4, 2024 Category: General Medicine Source Type: news

Yogurt Can Now Claim It May Reduce the Risk of Diabetes
Yogurt sold in the U.S. can make claims that the food may reduce the risk of type 2 diabetes, based on limited evidence, the U.S. Food and Drug Administration said Friday. The agency agreed that there is some evidence, but not significant scientific agreement, that eating at least 2 cups of yogurt per week may reduce the chance of developing the disease that affects about 36 million Americans. FDA has allowed qualified health claims—a claim that lacks full scientific support but is allowed as long as there are disclaimers to keep from misleading consumers—for dietary supplements since 2000 and foods since...
Source: TIME: Health - March 2, 2024 Category: Consumer Health News Authors: JONEL ALECCIA/AP Tags: Uncategorized healthscienceclimate wire Source Type: news

FDA Approves Exblifep (cefepime/enmetazobactam) for the Treatment of Complicated Urinary Tract Infections
SAINT-LOUIS, France& WEILL AM RHEIN, Germany February 27, 2024 -- Allecra Therapeutics (“Allecra”), a biopharmaceutical company developing novel therapies to combat antibiotic resistance, announced today that the U.S. Food and Drug... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 27, 2024 Category: Drugs & Pharmacology Source Type: news

FDA Approves Antibiotic Combination for Complicated UTIs
(MedPage Today) -- The FDA approved the combination of cefepime and enmetazobactam (Exblifep) for the treatment of adult patients with complicated urinary tract infections, including pyelonephritis. The agency's decision was based on data from... (Source: MedPage Today OB/GYN)
Source: MedPage Today OB/GYN - February 24, 2024 Category: OBGYN Source Type: news

Venatorx expects FDA ruling on its potential flagship product this week after years in development
Venatorx Pharmaceuticals' potential flagship product, cefepime-taniborbactam, is an investigational combination antibiotic being developed to treat adults with complicated urinary tract infections. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 21, 2024 Category: Pharmaceuticals Authors: John George Source Type: news

Cefepime-Taniborbactam Superior to Meropenem for Complicated UTI
THURSDAY, Feb. 15, 2024 -- For adults with complicated urinary tract infection (UTI), including acute pyelonephritis, cefepime-taniborbactam is superior to meropenem, according to a study published in the Feb. 15 issue of the New England Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 15, 2024 Category: Pharmaceuticals Source Type: news

Novel Antibiotic Combo Bests Meropenem for Complicated UTIs
(MedPage Today) -- Cefepime-taniborbactam, an investigational beta-lactam and beta-lactamase inhibitor combination, was superior to meropenem for the treatment of hospitalized patients with complicated urinary tract infection (UTI), including acute... (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - February 15, 2024 Category: Infectious Diseases Source Type: news

Novel Oral Antibiotic Effective Against Uncomplicated UTIs
(MedPage Today) -- Gepotidacin -- a first-in-class oral antibiotic -- appeared effective and safe for the treatment of uncomplicated urinary tract infections (UTIs) in a pair of large, phase III non-inferiority studies. In the two trials... (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - February 12, 2024 Category: Infectious Diseases Source Type: news

Orchid Pharma's new antibiotic 'Exblifeb' gets European Medicines Agency approval
The Chennai-based firm said Exblifeb incorporates Enmetazobactam, "the first completely invented-in-India Beta Lactamase inhibitor" and it is designed to address the global challenge of antimicrobial resistance (AMR). Exblifeb' demonstrates remarkable efficacy in treating complicated urinary tract infections (UTI), pneumonia, and bacteremia caused by extended spectrum beta-lactamase producing pathogens, Orchid Pharma said in a regulatory filing. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 30, 2024 Category: Pharmaceuticals Source Type: news

Europe Approves Exblifep for UTIs and Pneumonia Europe Approves Exblifep for UTIs and Pneumonia
Exblifep is as effective as piperacillin-tazobactam in the treatment of complicated urinary tract infections, the European Medicines Agency said.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - January 26, 2024 Category: Drugs & Pharmacology Tags: Urology Source Type: news

UTI: This common infection can be serious
A urinary tract infection (UTI) is common, but it can be serious. "Simple urinary tract infections can be managed by your primary care provider, but when they become complex leading to other issues or problems, you should seek the care of a specialist," says Dr. Mitchell Humphreys, a urologist at Mayo Clinic. What is a UTI? The urinary system helps the body eliminate waste, excess water and salt. It encompasses the kidneys, ureters, bladder and… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - January 12, 2024 Category: Databases & Libraries Source Type: news

Incidence of Pediatric UTI Decreased in Early Pandemic Period
WEDNESDAY, Jan. 3, 2024 -- The incidence of pediatric urinary tract infection (UTI) decreased during the early prepandemic period, with no increase in disease severity, according to a study published online Jan. 3 in JAMA Network Open.Danni Liang,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 3, 2024 Category: Pharmaceuticals Source Type: news

Improvement Needed in Managing UTI in Patients With Neurogenic Bladder
TUESDAY, Jan. 2, 2024 -- Expansion of caregiver involvement, enhancement of patient-provider communication, and targeting providers and care settings that lack familiarity with neurogenic bladder (NB) could improve urinary tract infection (UTI)... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 2, 2024 Category: Pharmaceuticals Source Type: news

DR ELLIE CANNON: Why can't high-tech scans spot the cause of my son's UTI pain?
DR ELLIE CANNON: Today's reader is seeking advice on behalf of her 35-year-old who has a long-running urinary tract infection which doctors are struggling to discover the cause. (Source: the Mail online | Health)
Source: the Mail online | Health - December 31, 2023 Category: Consumer Health News Source Type: news

Five-Day Antibiotic Course Noninferior for Pediatric Febrile UTI
TUESDAY, Dec. 26, 2023 -- For young children with febrile urinary tract infection (fUTI), a five-day amoxicillin-clavulanate course is noninferior to a 10-day course for recurrence of UTI within 30 days after completion of therapy, according to a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 26, 2023 Category: Pharmaceuticals Source Type: news